Skip to content

OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)

OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02335957
Acronym
OPTIMAL
Enrollment
489
Registered
2015-01-12
Start date
2015-04-30
Completion date
2021-07-31
Last updated
2022-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The main purpose of this study is to show the non-inferiority of the incidental irradiation, as compared to intentional irradiation of the axillary nodes, in terms of 5-years disease-free survival (DFS) of early stage breast cancer patients with limited affectation of sentinel node assessed by OSNA (250 to 15,000 copies/uL), treated with breast-conservative surgery without axillary lymphadenectomy.

Detailed description

Since long, the standard loco-regional treatment of the early-stage breast cancer is breast conservative surgery (tumorectomy) followed by a selective biopsy of the sentinel lymph node and, if positive, lymphadenectomy of axillary levels I and II. Complementary irradiation of the breast and ganglionar areas has shown to reduce disease-specific mortality. Therefore, adjuvant radiotherapy of the whole breast is currently indicated after conservative surgery. The recommendation to irradiate axillary lymph nodes is clear in patients with more than three affected nodes. The standard volumes to irradiate after lymphadenectomy include supraclavicular and level III axillary regions, while axillary levels I and II, and the internal breast lymph node chain, are reserved for cases of cumbersome axillary affectation, patients who have not undergone lymphadenectomy or it was insufficient, or affectation of the internal breast lymph node chain. However, when only 1 to 3 nodes are affected, there is no unanimity on the recommendation of radiotherapy, despite some studies have shown that irradiation improves survival. In addition, the National Cancer Institute of Canada trial (NCIC-CTGMA20), high risk patients with negative lymph nodes and patients with positive lymph nodes (most of them with 1 to 3 affected nodes) showed that local irradiation with or without regional lymph node irradiation improved disease-free survival, as well as loco-regional and distant disease control. Moreover, a systematic review including more than 20,000 patients from 45 studies concludes that the irradiation of the breast reduced the loco-regional relapse, even in patients without affected lymph nodes. One Step Nucleic Acid Amplification (OSNA) is a technique developed by Sysmex Corporation that allows a readily and complete analysis of sentinel lymph nodes during surgery. OSNA provides a quantification of the Cytokeratin 19 (CK19) tumour cell marker in the messenger ribonucleic acid (mRNA) of the sentinel node, the result being expressed as total tumour load (TTL), which is a discrete number of copies per microliter. This technique has shown ability to discriminate macrometastasis, micrometastasis or negativity, and to predict affectation of non-sentinel lymph nodes. According to previous results, a TTL \< 15,000 is associated with a 85% probability of non-affectation of (non-sentinel) axillar lymph nodes. The therapeutic value of the axillary lymphadenectomy has been questioned since long, and the recent publication of the Z0011 study proposes solely a selective biopsy of the sentinel lymph node. This has impacted clinical practice guidelines as prestigious as those of the National Comprehensive Cancer Network; however, irradiation is always considered in these cases. In summary, the amount of nodal volumes to irradiate in early stages of breast cancer is under discussion, particularly in the case of patients not submitted to axillar lymphadenectomy despite affectation of sentinel lymph nodes. In most cases, the irradiation of the breast implies incidental irradiation of the axillary level I, and in some cases the level II. For this reason, some groups have decided not to irradiate these axillary regions intentionally, while others advocate irradiating these regions intentionally.

Interventions

RADIATIONIrradiation

Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.

Sponsors

Grupo de Investigación Clínica en Oncología Radioterapia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Infiltrating, ductal carcinoma of the breast. 2. Treated with conservative surgery (tumorectomy or quadrantectomy) without lymphadenectomy. 3. Sentinel lymph node assessed by OSNA, with TTL in the range 250 - 15,000 copies/μL. 4. Age ≥ 18 yrs old. 5. Karnofsky Index ≥ 70 %. 6. Signed Informed Consent.

Exclusion criteria

1. Other types of breast cancer different from infiltrating ductal carcinoma. 2. Bilateral breast cancer. 3. Males. 4. Mastectomy or axillary homolateral lymph node dissection. 5. Previous thoracic irradiation therapy. 6. Systemic neoadjuvant therapy previous to surgery. 7. Contraindications of radiotherapy (pregnancy, severe collagen diseases). 8. Other neoplasms. 9. Severe associated comorbidities that, according to the investigator criteria, may interfere with the study evaluations.

Design outcomes

Primary

MeasureTime frameDescription
Disease Free Survival5 yearsThe primary outcome will be the 5-years DFS. DFS is defined as the time from randomization to any breast cancer-related event, including local, regional or distant recurrence, or death from breast cancer.

Secondary

MeasureTime frameDescription
Time to loco-regional recurrence up 5-years5 yearsLoco-regional recurrence during the 5-years follow-up, defined as clinical or image-based detection of tumour in treated breast (local recurrence) or in the ipsilateral axilla or supraclavicular fossa (regional recurrence).
Total irradiation dose (Gy) received in axillary levels I, II and III, supraclavicular fossa, and internal mammary chain volumes, at the end of radiotherapy.2 yearsTotal dose (Gy) received in axillary levels I, II,and II, supraclavicular, and internal mammary chain volumes.
Time to distant recurrence up 5-years5 yearsDistant recurrence occuring during the 5-years follow-up, defined as defined as clinical or image-based detection of neoplastic affectation of other organs or tissues different from the treated breast, ipsilateral axilla or supraclavicular fossa.
Number of patients with acute toxicity, defined as any adverse event appearing up to one month after finalization of radiotherapy.7 yearsAcute toxicity, assessed by a selected subset of the Common Terminology Criteria for Adverse Events v4.0 (CTCAE)
Number of patients with chronic toxicity, defined as any adverse event appearing during follow-up, up to 5 years.7 yearsChronic toxicity , assessed by a selected subset of the Common Terminology Criteria for Adverse Events v4.0 (CTCAE)

Countries

Italy, Portugal, Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026